Search for European Projects

8 European Projects Found

Searched on 125080 European Projects

 ONGOING 
Pharmacogenomics is the study of genetic variability affecting an individual’s response to a drug. Its use allows personalized medicine and reduction in ‘trial and error’ prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx consortium will investigate a pre-emptive genotyping approach (that is: multiple pharmacogenomic variants are collected prospectively and ...
Read Project

 16

 FINISHED 
Lifestyle, disease and biology put older people at risk of functional decline, leading to falls, cognitive impairment, frailty, and negative consequences for quality of life. PreventIT will develop and test an ICT based mHealth System (iPAS) for the consumer market that 1) enables early identification of risk of age-related functional decline, and 2) engenders behavioural change in younger older a ...
Read Project

 10

 FINISHED 
Human epithelia are permanently challenged by microorganisms. In the gut, the fraction of strict anaerobic bacteria increases from proximal to distal, reaching 99% of bacterial species in the colon. Moreover, microbial metabolism causes a reduction of the environment to a low redox potential of only –200 mV to –300 mV. Defensins, characterised by three intramolecular disulfide-bridges, are key eff ...
Read Project

 2

 FINISHED 
Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate in costly late-stage clinical trials. The PREDECT consortium will focus on complex but transferable, next generation in vitro and in vivo models for breast, prostate and lung cancers. Models will be investigated for their improved potential to validate novel th ...
Read Project

 23

 FINISHED 
HYPOTHESIS: Early inhalation of Budesonide (BS) reduces the absolute risk of developing bronchopulmonary dysplasia (BPD) or death in preterm infants born between 23 and 27 weeks gestational age (GA) by 10%. PRIMARY OBJECTIVE: Survival without BPD at 36 weeks GA. SECONDARY OBJECTIVES: (1) neurodevelopment at a corrected age of 18-22 months; (2) adverse treatment effects; (3) mortality at 36 weeks G ...
Read Project

 15

 FINISHED 
Pharmacogenomics is the scientific discipline that relates inter-individual variation in drug response to genetic variation. While there have been major advances in basic genomic knowledge and genotyping technologies, translation into clinical practice has been slow. It is essential we quicken the pace of translational research in pharmacogenomics - at present, we cannot define which patients are ...
Read Project

 7

 FINISHED 
The objective of the HEALTH-2009-2.3.1-2 call is to study the impact of different antibiotics on the prevalence of resistant bacteria in the human host. In ANTIRESDEV we will achieve this objective using the approaches suggested in the call as follows. We will use culture-based and culture-independent approaches to investigate the impact of four different types of antibiotics (with different modes ...
Read Project

 12

 FINISHED 

Novel anti-inflammatory compounds for autoimmune diseases (KINACEPT)

Start date: Dec 1, 2008, End date: Nov 30, 2010,

"The consortium has a lead series of p38 inhibitors with unusual anti-inflammatory properties. The drug leads were originally elaborated as a potential therapy for inflammatory bowel disease, however, the potency of the compounds and their general anti-inflammatory mode of action has raised the possibility of studying their utility in other diseases including rheumatoid arthritis. In addition ...
Read Project

 10